Industry News
Pharmaceutical Industry News
With sales of potential…
With sales of potential blockbuster Lokelma scaling up, AstraZeneca is bolstering its production of the hyperkalemia treatment with a $445 million injection of funds. The investment will increase the capabilities of AZ’s manufacturing facility in
Through the agreement, Scynexis…
Through the agreement, Scynexis will oblige GSK's request to wind down its phase 3 study of antifungal med Brexafemme in invasive candidiasis, which it had restarted after the FDA lifted a clinical hold earlier this
In addition to substantial spray…
In addition to substantial spray drying capacity, new CDMO Codis says it's also equipped to handle commercial-scale work on amorphous solid dispersions, particle engineering and finished dose manufacturing for pharma, consumer health and over-the- counter
GSK’s study evaluated the…
GSK's study evaluated the tolerability and acceptability of its long-acting pre-exposure prophylaxis drug Apretude compared with Gilead's rival Yeztugo.
After Rezdiffra’s approval and…
After Rezdiffra’s approval and Wegovy’s label expansion, the race is on in metabolic dysfunction-associated steatohepatitis. M&A deals totaling more than $10 billion in recent months show major pharma players still see sizable opportunity in the
Just a few months after surfacing…
Just a few months after surfacing at Orca Bio following his early 2025 departure from Legend Biotech, Steve Gavel has taken on the chief commercial officer role at yet another cell therapy biotech.
In a new episode of The Top Line,…
In a new episode of The Top Line, Salesforce’s president of regulated industries explains why life science companies should embrace digital transformation and rethink engagement with patients and providers.
The positive readout could move…
The positive readout could move Tukysa, which has been used for second-line, HER2-positive breast cancer, into the earlier, first-line maintenance setting.
With two Trump administration drug…
With two Trump administration drug pricing deals in the books and more likely on the way, the U.S. policy environment could soon stabilize for many Big Pharma companies. That put Johnson & Johnson in an
As BioNTech works to establish a…
As BioNTech works to establish a production footprint for mRNA vaccines in Africa, two EU groups have offered financial backing to the company's efforts.
Opioid Deaths Suddenly Dominate a Governor’s Race. Here’s What We Know.
Representative Mikie Sherrill, a New Jersey Democrat, said a firm once owned by her Republican opponent, Jack Ciattarelli, spread misinformation about opioids. His campaign has threatened to sue her for defamation.
W.H.O. Warns of Sharp Increase in Drug-Resistant Infections
The U.N. health agency found that one in six infections worldwide was resistant to the most commonly available antibiotics.
The FDA has tagged Novo Nordisk’s…
The FDA has tagged Novo Nordisk's newly acquired manufacturing facility in Indiana with an official action indicated label, which is the most severe of the three inspection classifications issued by the agency.
Syngene: Transforming Monoclonal…
Syngene: Transforming Monoclonal Antibody Manufacturing for the Next Wave of Biologics
With the launch of a new branded…
With the launch of a new branded initiative, Bristol Myers Squibb is crafting a recipe for both ramping up its Cobenfy rollout and boosting schizophrenia awareness and education.
The FDA has adjusted the label of…
The FDA has adjusted the label of Johnson & Johnson and Legend Biotech’s Carvykti, warning patients and doctors that use of the multiple myeloma treatment could increase the risk an intestinal inflammatory disorder which can
Germany’s LTS—whose…
Germany's LTS—whose bread-and-butter business revolves around developing and manufacturing drug delivery systems—is paying an undisclosed sum to purchase U.S. CDMO Renaissance Lakewood, which itself specializes in nasals sprays and sterile dosage forms.
Halozyme scoured very broadly for…
Halozyme scoured very broadly for potential acquisitions in the drug delivery field before landing on Elektrofi, Halozyme CEO Helen Torley said during an interview on the sidelines of Fierce Biotech Week in Boston.
Trump Cuts a Deal With AstraZeneca to Lower Drug Prices
The president and top health officials acknowledged using the leverage of tariff threats to forge an agreement. Other companies are still in negotiations with the White House.
President Donald Trump has been…
President Donald Trump has been pressuring top drugmakers to get on board with his drug pricing agenda for months. Now, AstraZeneca is ready to comply, MSNBC reports.